Literature DB >> 21145606

Sequentially delivered boost plans are superior to simultaneously delivered plans in head and neck cancer when the boost volume is located further away from the parotid glands.

Emmy Lamers-Kuijper1, Wilma Heemsbergen, Anke van Mourik, Coen Rasch.   

Abstract

PURPOSE: To find parameters that predict which head and neck patients benefit from a sequentially delivered boost treatment plan compared to a simultaneously delivered plan, with the aim to spare the salivary glands. METHODS AND MATERIALS: We evaluated 50 recently treated head and neck cancer patients. Apart from the clinical plan with a sequentially (SEQ) given boost using an Intensity Modulated Radiotherapy Technique (IMRT), a simultaneous integrated boost (SIB) technique plan was constructed with the same beam set-up. The mean dose to the parotid glands was calculated and compared. The elective nodal areas were bilateral in all cases, with a boost on either one side or both sides of the neck.
RESULTS: When the parotid gland volume and the Planning Target Volume (PTV) for the boost overlap there is on average a lower dose to the parotid gland with a SIB technique (-1.2 Gy), which is, however, not significant (p=0.08). For all parotid glands with no boost PTV overlap, there is a benefit from a SEQ technique compared to a SIB technique for the gland evaluated (on average a 2.5 Gy lower dose to the parotid gland, p<0.001). When the distance between gland and PTV is 0-1 cm, this difference is on average 0.8 Gy, for 1-2 cm distance 2.9 Gy and for glands with a distance greater than 2 cm, 3.3 Gy. When the lymph nodes on the evaluated side are also included in the boost PTV, however, this relationship between the distance and the gain of a SEQ seems less clear.
CONCLUSIONS: A sequentially delivered boost technique results in a better treatment plan for most cases, compared to a simultaneous integrated boost IMRT technique, if the boost PTV is more than 1 cm away from at least one parotid gland. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21145606     DOI: 10.1016/j.radonc.2010.10.024

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.

Authors:  Tamer Refaat; Mehee Choi; Tarita O Thomas; Ian Bacchus; Mark Agulnik; Harold J Pelzer; Ann L Mellott; Alfred W Rademaker; Dachao Liu; Vythialinga Sathiaseelan; Bharat B Mittal
Journal:  Am J Clin Oncol       Date:  2015-12       Impact factor: 2.339

2.  Preliminary analysis of the sequential simultaneous integrated boost technique for intensity-modulated radiotherapy for head and neck cancers.

Authors:  Masayoshi Miyazaki; Kinji Nishiyama; Yoshihiro Ueda; Shingo Ohira; Katsutomo Tsujii; Masaru Isono; Akira Masaoka; Teruki Teshima
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

3.  A comparison of clinical outcomes between simultaneous integrated boost (SIB) versus sequential boost (SEQ) intensity modulated radiation therapy (IMRT) for head and neck cancer: A meta-analysis.

Authors:  Li Jiang; Yong Zhang; Zhendong Yang; Feifei Liang; Jiangtao Wu; Rensheng Wang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

4.  Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis.

Authors:  Yao-Hung Kuo; Ji-An Liang; Tang-Chuan Wang; Chun-Jung Juan; Chia-Chin Li; Chun-Ru Chien
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

5.  Single-Institute Clinical Experiences Using Whole-Field Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential IMRT in Postoperative Patients With Oral Cavity Cancer (OCC).

Authors:  Chen-Hsi Hsieh; Pei-Wei Shueng; Li-Ying Wang; Li-Jen Liao; Wu-Chia Lo; Hsin-Pei Yeh; Hsiu-Ling Chou; Le-Jung Wu
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.